Clinical trials: Disease, Acute
Acute Myeloid Leukemia
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
The main objective of this study is to compare conventional chemotherapy: daunorubicin and the Aracytine and this chemotherapy in combination with the monoclonal antibody used Mylotarg in divided doses.
- Trial name
- NCT00927498
- Testing
- conventional chemotherapy (AraC + Daunorubicin),, Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
- Where
- 19 sites in France
- Volunteers
- 280 people
- Sponsor
- Acute Leukemia French Association
Pain, Acute
Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain
The objective of this study is to evaluate the potential opioid-sparing effect associated with the novel combination of fentanyl and sub-dissociative ketamine in adult patients with moderate to severe pain in the emergency…
- Trial name
- NCT03959852
- Testing
- Fentanyl, Fentanyl and Ketamine, Ketamine
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Mercy Health Ohio
Diabetes Mellitus, Type 2, Acute Heart Failure
EMPA Acute Heart Failure
In this study the investigators are aiming to treat patients with acute heart failure with or without diabetes with Empagliflozin or placebo.
- Trial name
- NCT03554200
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- RWTH Aachen University
Chronic Kidney Diseases, Acute Kidney Injury
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone.
- Conditions
- Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- Trial name
- NAD agent (NCT06866236)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Ebima Clifford Okundaye
Heart Failure, Acute Kidney Injury
Furosemide Stress Test for the Prediction of Acute Kidney Injury Severity in Acute Heart Failure Patients
This study is aim to study the changes of serum creatinine levels at 72 hours after admission in patients with acute heart failure who has diuretic resistance compared to those who do not have diuretic resistance from furosemide…
- Trial name
- NCT04464811
- Testing
- Furosemide stress test
- Where
- Thailand
- Volunteers
- 257 people
- Sponsor
- Chiang Mai University
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
COPD Exacerbation
Biomarker of Acute Exacerbation of COPD
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the main factor that leads to the deterioration of the disease.
- Trial name
- NCT04963244
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pediatric Acute Lymphoblastic Leukemia
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3.
- Trial name
- HR ALL (NCT06184009)
- Testing
- ALL, High risk
- Where
- 9 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- Jae Wook Lee
SARS-CoV Infection, Acute Respiratory Distress Syndrome
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
A randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose, phase II study to evaluate the efficacy and safety of glenzocimab in ARDS.
- Conditions
- SARS-CoV Infection, Acute Respiratory Distress Syndrome, COVID-19, ARDS
- Trial name
- GARDEN (NCT04659109)
- Testing
- glenzocimab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Acticor Biotech
Ischemia Reperfusion Injury, Cardiac Surgery Associated - Acute Kidney Injury
A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)
This is a Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a clinical trial of BX-001N to prevent patients from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and subsequent Major Adverse Kidney Events…
- Trial name
- NCT07164833
- Testing
- BX-001N Experimental group 1, BX-001N Experimental group 2
- Where
- 8 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Bilix Co.,Ltd.
Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute…
- Trial name
- NCT01802333
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride
- Where
- 447 sites in United States, Canada
- Volunteers
- 754 people
- Sponsor
- National Cancer Institute (NCI)
Sepsis, Acute Lung Injury
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
This is a prospective, randomized (1:1), double-blind, multi-center, Phase II clinical study to test the safety and efficacy of a recombinant chimeric anti-tissue factor antibody (ALT-836) versus placebo in patients with sepsis…
- Conditions
- Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT00879606
- Testing
- ALT-836
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Altor BioScience
Pruritus
In-Use Test With a Cosmetic Product to Treat Pruritus
The aim of the study is to evaluate the cosmetic features of the product WO 3308 by means of a questionnaire in an interview situation after two weeks of product treatment, giving special consideration to the cosmetic…
- Trial name
- NCT03477058
- Testing
- WO 3308 cosmetic product for topical use
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Spinal Cord Injuries, Physical Inactivity
An Online Rehabilitation Programme for People with SCI
The goal of this feasibility study is to explore the feasibility and effectiveness of a 12-week online rehabilitation programme in people with Spinal Cord Injury during the transition from hospital to home.
- Conditions
- Spinal Cord Injuries, Physical Inactivity, Spinal Cord Injury, Acute
- Trial name
- NCT06583538
- Testing
- Giraffe Healthcare
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Glasgow Caledonian University
Acute Myeloid Leukemia, Relapse Leukemia
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
The vast majority of patients with AML will die of the disease, and no standard chemotherapy regimen were defined for patients with relapsed/refractory AML.
- Trial name
- NCT03181815
- Testing
- Cladribine, G-CSF, Aclarubicin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Myelofibrosis, Acute Lymphocytic Leukemia (ALL)
Expanded Access to Navitoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
- Trial name
- NCT03592576
- Testing
- Navitoclax, Venetoclax
- Sponsor
- AbbVie
Acute Renal Failure, Critical Illness
Characterization of the Efficacy of Furosemide Depending on Albumin Function
During this prospective, uncontrolled and non-interventional observational study, the influence of albumin function on the efficacy of furosemide will be investigated.
- Trial name
- NCT04972617
- Testing
- albumin function analysis (ABIC)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Rostock
Leukemia
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003868
- Testing
- cyclophosphamide, methotrexate, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Respiratory Distress Syndrome
PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome.
The PaO2/FiO2 (P/F) ratio is same for all the Positive End Expiratory Pressure (PEEP) ≥ to 5. This P/F ratio misleads the severity of disease without the knowledge of set PEEP.
- Trial name
- NCT03946150
- Testing
- P/FP Ratio
- Where
- Singapore
- Volunteers
- 4,361 people
- Sponsor
- National University Health System, Singapore
Covid19, Corona Virus Infection
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
The world is currently experiencing a coronavirus (CoV-2) pandemic. A new (SARS)-CoV infection epidemic began in Wuhan, Hubei, China, in late 2019; originally called 2019- nCoV the virus is now known as SARSCoV- 2 and the disease…
- Conditions
- Covid19, Corona Virus Infection, ARDS, Aviptadil
- Trial name
- NCT04536350
- Testing
- Aviptadil 67μg
- Where
- 2 sites in Switzerland
- Volunteers
- 83 people
- Sponsor
- Prof. Dr. Jörg Leuppi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.